Broad therapeutic benefit of myosin inhibition in hypertrophic cardiomyopathy

Laura Sen-Martín,Ángel Fernández-Trasancos,Miguel Á. López-Unzu,Divya Pathak,Alessia Ferrarini,Verónica Labrador-Cantarero,David Sánchez-Ortiz,María Rosaria Pricolo,Natalia Vicente,Diana Velázquez-Carreras,Lucía Sánchez-García,Jose Ángel Nicolás-Ávila,María Sánchez-Díaz,Saskia Schlossarek,Lorena Cussó,Manuel Desco,María Villalba-Orero,Gabriela Guzmán-Martínez,Enrique Calvo,Roberto Barriales-Villa,Jesús Vázquez,Fátima Sánchez-Cabo,Andrés Hidalgo,Lucie Carrier,James A. Spudich,Kathleen M. Ruppel,Jorge Alegre-Cebollada

DOI: https://doi.org/10.1101/2024.03.22.584986

2024-03-27

Abstract:Myosin inhibitor mavacamten is the only targeted treatment available for hypertrophic cardiomyopathy (HCM), a disease caused by hundreds of genetic variants that affect mainly sarcomeric myosin and its negative regulator cardiac myosin-binding protein C (cMyBP-C, encoded by ). Here, we have examined whether the reported limited efficacy of mavacamten in a fraction of HCM patients can result from dissimilar HCM pathomechanisms triggered by different genetic variants, a scenario particularly relevant for -associated HCM. To this aim, we have generated knock-in mice including missense pathogenic variant cMyBP-C p.R502W, which, different from patients who carry truncations in the protein, develop progressive pathogenic myocardial remodeling in the absence of alterations of cMyBP-C levels and localization. Mechanistically, we find that mutation R502W reduces the binding affinity of cMyBP-C for myosin without inducing a shift towards more active myosin conformations as observed when cMyBP-C levels are reduced. Despite these diverging molecular alterations, we show that mavacamten blunts myocardial remodeling both in R502W and cMyBP-C-deficient, knock-out hearts. These beneficial effects are accompanied by improved tolerance to exercise only in R502W animals. Hence, our results indicate that myosin inhibition is effective to treat HCM caused by both truncating and missense variants in regardless of the primary pathomechanisms they elicit.

Physiology

What problem does this paper attempt to address?

The paper aims to explore the therapeutic effects of the myosin inhibitor mavacamten on hypertrophic cardiomyopathy (HCM), particularly its efficacy in HCM caused by different genetic variants of cardiac myosin-binding protein C (cMyBP-C). Specifically, the study focuses on the following points:

1. **Background and Problem**: HCM is a common familial heart disease, affecting approximately 0.5% of the population. This disease is usually caused by various genetic mutations, the most common of which are mutations in the MYH7 and MYBPC3 genes. Currently, the only targeted therapeutic drug is mavacamten, but some patients do not respond well to this medication.

2. **Research Objective**: The paper attempts to investigate whether different types of MYBPC3 mutations affect the efficacy of mavacamten by constructing a new mouse model. Special attention is given to those variants that do not lead to a decrease in cMyBP-C protein levels, such as the cMyBP-C p.R502W variant.

3. **Experimental Design**: Researchers generated a mouse model carrying the cMyBP-C p.R502W variant and conducted a comprehensive analysis of its cardiac structure, function, and gene expression. By comparing wild-type mice and mutant mice, the study evaluated the impact of mavacamten on different types of HCM.

4. **Main Findings**: The results showed that although the R502W variant does not alter the expression level or localization of cMyBP-C, it still leads to typical HCM pathological features. Importantly, mavacamten demonstrated good therapeutic effects in both R502W mice and cMyBP-C-deficient mice, significantly reducing cardiomyocyte hypertrophy and fibrosis.

In summary, the core issue of the paper is to verify whether mavacamten can effectively treat HCM caused by different mechanisms, with particular attention to those variants that do not lead to a decrease in cMyBP-C levels. The research results indicate that mavacamten has good efficacy for various types of MYBPC3 mutations.